Bavarian Nordic ASCHIX:BAVAC 84 Net Margin % is 1.60% as of Mar. 2026, which is 80% below its 10-year median of 8.14. GuruFocus rates CHIX:BAVAC with a GF Score™ of 84/100 and a GF Value™ of kr175.27 (Fairly Valued). The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Bavarian Nordic AS ranks better than 87.22% on this metric.
The historical rank and industry rank for Bavarian Nordic AS's Net Margin % or its related term are showing as below:
CHIX:BAVAc'
s Net Margin % Range Over the Past 10 Years
Min: -72.3 Med: 8.14 Max: 22.03
Current: 19.71
CHIX:BAVAc's Net Margin % is ranked better than 87.22% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs CHIX:BAVAc: 19.71
Bavarian Nordic AS (CHIX:BAVAc) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bavarian Nordic AS Net Margin % Related Terms
Bavarian Nordic AS Net Margin % Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a Net Margin % of 1.60% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bavarian Nordic AS and its competitors. This is 80% below median its historical median of 8.14. According to the industry distribution chart, Bavarian Nordic AS ranks #121 out of 947 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Bavarian Nordic AS's Net Margin % too high?
Bavarian Nordic AS's current Net Margin % of 1.60% is 80% below median its 10-year median of 8.14. Based on the distribution chart, Bavarian Nordic AS ranks #121 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #121 out of 947 companies for Net Margin %. This places Bavarian Nordic AS in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bavarian Nordic AS and its competitors. Bavarian Nordic AS's current Net Margin % is 1.60%, which is 80% below median its own 10-year median of 8.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Fairly Valued. The stock's GF Value™ is kr175.27, compared to a current price of kr188.30 — trading 7.4% above its estimated fair value. The current Net Margin % is 1.60%, which is 80% below median its 10-year median of 8.14. Bavarian Nordic AS's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Net Margin % is 1.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 7.4% above its estimated GF Value™ of kr175.27.
GuruFocus considers Bavarian Nordic AS to be Fairly Valued.
Key valuation signals for CHIX:BAVAC:
Net Margin %: 1.60% (80% below median its 10-year median of 8.14)
GF Value™: kr175.27 vs. price of kr188.30 (7.4% above fair value)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
84GF Score
Get the complete analysis for CHIX:BAVAC
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
